Vivo Capital | Activity | F4Vivo Capital Activity
Every public signal F4 has attached to this firm, with sources and cross-entity links.
News
Marked its 30th anniversary by launching a new philanthropic initiative tied to healthcare innovation.
Vivo Capital 30th anniversary philanthropic initiative
Led Full-Life Technologies' $150M financing package for its global radiotherapeutics platform.
Exit
Portfolio company Ajax Therapeutics was acquired by Eli Lilly in a deal worth up to $2.3B.
Ajax Therapeutics
Investment
Co-led Oricell Therapeutics' $110M pre-IPO financing round to accelerate global CAR-T development.
Oricell Therapeutics
Essay
Co-founders published a letter reflecting on the firm's 30-year history in healthcare investing.
A Letter From Our Co-Founders: Celebrating Vivo Capital's 30th Anniversary
4 exits· FEB 2026 – APR 2026Show all
Exit
Portfolio company Soleno Therapeutics was acquired by Neurocrine Biosciences for $2.9B.
Soleno Therapeutics
Exit
Portfolio company Terns Pharmaceuticals was acquired by Merck for $6.7B.
Terns Pharmaceuticals
Exit
Portfolio company Scientia Vascular was acquired by Medtronic for $550M.
Scientia Vascular
Exit
Portfolio company 35Pharma was acquired by GSK for $950M.
35Pharma
Investment
Participated in Kinaset Therapeutics' $103M oversubscribed Series B for an inhaled pan-JAK inhibitor in respiratory disease.
Kinaset Therapeutics
New Fund
Closed its public equity fund with commitments of over $740 million.
Vivo Opportunity (public) fund close